JP5473937B2 - 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド - Google Patents

膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド Download PDF

Info

Publication number
JP5473937B2
JP5473937B2 JP2010538291A JP2010538291A JP5473937B2 JP 5473937 B2 JP5473937 B2 JP 5473937B2 JP 2010538291 A JP2010538291 A JP 2010538291A JP 2010538291 A JP2010538291 A JP 2010538291A JP 5473937 B2 JP5473937 B2 JP 5473937B2
Authority
JP
Japan
Prior art keywords
gemcitabine
treatment
cancer
pancreatic cancer
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2010538291A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011506492A5 (OSRAM
JP2011506492A (ja
Inventor
リン・ギャニオン
リリアン・ギアーツ
クリストファー・ペニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prometic Biosciences Inc
Original Assignee
Prometic Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc filed Critical Prometic Biosciences Inc
Publication of JP2011506492A publication Critical patent/JP2011506492A/ja
Publication of JP2011506492A5 publication Critical patent/JP2011506492A5/ja
Application granted granted Critical
Publication of JP5473937B2 publication Critical patent/JP5473937B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2010538291A 2007-12-19 2008-12-18 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド Expired - Fee Related JP5473937B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US812907P 2007-12-19 2007-12-19
US61/008,129 2007-12-19
PCT/CA2008/002190 WO2009076761A1 (en) 2007-12-19 2008-12-18 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer

Publications (3)

Publication Number Publication Date
JP2011506492A JP2011506492A (ja) 2011-03-03
JP2011506492A5 JP2011506492A5 (OSRAM) 2012-02-02
JP5473937B2 true JP5473937B2 (ja) 2014-04-16

Family

ID=40795145

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010538291A Expired - Fee Related JP5473937B2 (ja) 2007-12-19 2008-12-18 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド

Country Status (15)

Country Link
US (1) US8946190B2 (OSRAM)
EP (1) EP2231166B1 (OSRAM)
JP (1) JP5473937B2 (OSRAM)
KR (1) KR101603351B1 (OSRAM)
CN (1) CN101903028B (OSRAM)
AU (1) AU2008338204B2 (OSRAM)
BR (1) BRPI0821395A2 (OSRAM)
CA (1) CA2708679C (OSRAM)
DK (1) DK2231166T3 (OSRAM)
ES (1) ES2414617T3 (OSRAM)
MX (1) MX2010006867A (OSRAM)
NZ (1) NZ586249A (OSRAM)
PT (1) PT2231166E (OSRAM)
TW (1) TWI448290B (OSRAM)
WO (1) WO2009076761A1 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2427416E (pt) 2009-05-04 2016-06-15 Prometic Pharma Smt Ltd Compostos aromáticos substituídos e seus usos farmacêuticos
SG10201807622WA (en) * 2010-10-27 2018-10-30 Prometic Pharma Smt Ltd Compounds and compositions for the treatment of cancer
CN102617679B (zh) * 2012-03-13 2014-11-26 北京大学 一种共轭亚油酸与吉西他滨连接的前体药物制备方法及其应用
US9737538B2 (en) 2013-02-12 2017-08-22 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP2956121B1 (en) 2013-02-12 2018-05-30 Bend Research, Inc. Solid dispersions of low-water solubility actives
EP3578170A1 (en) * 2013-02-28 2019-12-11 Basf As A composition comprising a lipid compound, a triglyceride, and a surfactant, and methods of using the same
WO2015116782A1 (en) 2014-01-29 2015-08-06 Board Of Regents, The University Of Texas System Nucleobase analogue derivatives and their applications
MA53188A1 (fr) 2018-10-11 2021-12-31 Basf As Composés aromatiques et leurs utilisations pharmaceutiques

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU641356B2 (en) * 1989-03-13 1993-09-23 Cellegy Pharmaceuticals, Inc. Treatment of skin diseases and tumors
US6982091B2 (en) * 2001-08-29 2006-01-03 Umd, Inc. Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy
US6340705B1 (en) * 1999-09-10 2002-01-22 Monsanto Technology, Llc Use of α-linolenic acid metabolites for treatment or prevention of cancer
WO2002083120A2 (en) 2001-04-18 2002-10-24 Prometic Biosciences Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20060012880A1 (en) * 2002-05-02 2006-01-19 Law Benjamin P Optical device with refractive and diffractive properties
AP2005003367A0 (en) * 2003-02-07 2005-09-30 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis.
ES2264886B1 (es) * 2005-05-12 2008-02-01 Proyecto Empresarial Brudy, S.L. Utilizacion de acido docosahexaenoico para el tratamiento de enfermedades tumorales.

Also Published As

Publication number Publication date
AU2008338204B2 (en) 2015-03-05
PT2231166E (pt) 2013-06-17
ES2414617T3 (es) 2013-07-22
TWI448290B (zh) 2014-08-11
DK2231166T3 (da) 2013-06-24
CA2708679A1 (en) 2009-06-25
EP2231166A4 (en) 2012-02-22
CA2708679C (en) 2016-11-15
CN101903028A (zh) 2010-12-01
WO2009076761A1 (en) 2009-06-25
TW200934494A (en) 2009-08-16
US8946190B2 (en) 2015-02-03
CN101903028B (zh) 2013-06-05
MX2010006867A (es) 2010-08-31
US20100273731A1 (en) 2010-10-28
JP2011506492A (ja) 2011-03-03
BRPI0821395A2 (pt) 2015-06-16
KR101603351B1 (ko) 2016-03-14
EP2231166B1 (en) 2013-03-20
KR20100101134A (ko) 2010-09-16
AU2008338204A1 (en) 2009-06-25
NZ586249A (en) 2012-05-25
HK1151244A1 (en) 2012-01-27
EP2231166A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
JP5473937B2 (ja) 膵臓癌の治療のためのゲムシタビンと併用した中鎖脂肪酸、その塩およびトリグリセリド
Zhao et al. The role of RICTOR amplification in targeted therapy and drug resistance
WO2017177962A1 (zh) 一种用于治疗胃癌的喹啉衍生物
US20120046314A1 (en) Nitroxides for use in treating or preventing neoplastic disease
US20050215530A1 (en) Combination therapy for the treatment of cancer
CN112566628A (zh) 预防和治疗癌症的药物组合物，包括棉酚、苯乙双胍和抗癌剂
US20210038537A1 (en) Emodin for Use in Regulating Expression of Proteins Involved in Inflammation
JP2023509191A (ja) 癌を治療するための組み合わせ療法
CN115135326B (zh) 作为c-Met激酶抑制剂的化合物的联用药物组合物及其用途
HK1151244B (en) Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer
JP2019123671A (ja) 前立腺がんの予防又は治療剤
JP4091639B2 (ja) チロシンキナーゼ阻害剤が惹起する皮膚障害の予防剤および／または処置剤
CN113786491A (zh) 一种含汉防己甲素、二氢槲皮素或槲皮素的抗肿瘤联用制剂
JP2005255643A (ja) 抗腫瘍効果増強方法および抗腫瘍効果増強剤
CN102939086B (zh) 胃癌的治疗方法
US20070269531A1 (en) Non-Steroid Anti-Inflammatory Agents with Vitamins, Minerals, and Dietary Supplements for the Prevention and Treatment of Primary, Secondary and Tertiary Cancer
RU2844464C2 (ru) Фармацевтическая композиция для профилактики или лечения трижды негативного рака молочной железы
CN119499386B (zh) 一种抗肿瘤药物的联合用药组合物
CN106176757B (zh) 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途
Deshmukh Modulation of Intestinal Flora as an Emerging Therapeutic Approach for the Treatment of Colon Cancer
Lu 3508 POSTER Hugl-1 mutation has a correlation with the hepatocellular carcinoma progression
HK40049617A (en) Pharmaceutical composition for preventing or treating cancer, comprising gossypol, phenformin, and anticancer agent
CN110755430A (zh) 一种vegfr抑制剂与降压药组合物及其应用
TW201021801A (en) A pharmaceutical composition for the treatment of cancers
TW201016214A (en) Synergistic pharmaceutical composition for the treatment of cancers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111206

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130618

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130917

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140204

R150 Certificate of patent or registration of utility model

Ref document number: 5473937

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S303 Written request for registration of pledge or change of pledge

Free format text: JAPANESE INTERMEDIATE CODE: R316303

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees